Back to search results

Study of Atumelnant for Congenital Adrenal Hyperplasia

This study is testing a medication called atumelnant in adults with classic Congenital Adrenal Hyperplasia (CAH), a genetic condition affecting hormone production. The main goal is to see how well atumelnant works and if it's safe. You might be able to join if you are between 18 and 74 years old and have classic CAH. Researchers will measure a hormone called A4 at Week 32 to see if atumelnant helps keep it within a normal range while you are on your usual steroid medication. About 150 people are expected to participate. The current status of this study is unclear.

Study design
This is a Phase 3, global, multicenter study. Participants will be randomly assigned to receive either atumelnant or a placebo, and neither you nor your doctor will know which you are receiving.
What's involved
After a 3 to 6-week screening period, you would take either atumelnant or a placebo once daily by mouth. The study will evaluate your A4 levels at Week 32.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 32, which gives an indication of the study's duration for evaluating the main outcome.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07144163

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Recruiting
PHASE3Ages 18–74InterventionalTreatment
Crinetics Pharmaceuticals Inc.
~150 participants
Updated 2026-09-02 on ClinicalTrials.gov
What's tested:AtumelnantPlacebo

At a glance

Recruiting sites
68 of 68 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants with morning post-GC A4 ≤ ULN who are on physiologic GC replacement.
Measured over Week 32

Conditions

Congenital Adrenal Hyperplasia
Classic Congenital Adrenal Hyperplasia

Explore related trials

Congenital Adrenal HyperplasiaCYP21A2 Gene

NCT07144163

Where you'd take part

This study runs at 68 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Crinetics Study Site

    Los Angeles, Californiano site contact published

    Recruiting

  • Crinetics Study Site

    Aurora, Coloradono site contact published

    Recruiting

  • Crinetics Study Site

    Gainesville, Floridano site contact published

    Recruiting

  • Crinetics Study Site

    Atlanta, Georgiano site contact published

    Recruiting

  • Crinetics Study Site

    Chicago, Illinoisno site contact published

    Recruiting

  • Crinetics Study Site

    Baltimore, Marylandno site contact published

    Recruiting

  • Crinetics Study Site

    Ann Arbor, Michiganno site contact published

    Recruiting

  • Crinetics Study Site

    Minneapolis, Minnesotano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Crinetics Clinical Trials
[email protected]
833-827-9741
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

A4 \>ULN and treated with \<11 mg/m2/day (physiologic) GC doses
OR normal A4 (\>0.5xULN to ≤1xULN) and treated with ≥14 mg/m2/day GC doses
OR A4 \>ULN and treated with ≥11 mg/m2/day GC doses. 5. On a stable (defined as no dose change of \>5 mg/day hydrocortisone equivalent within 2 months prior to Screening) regimen of GC replacement (e.g., hydrocortisone, prednisolone, prednisone, methylprednisolone, meprednisone, dexamethasone, cortisone acetate) at the time of informed consent. 6. If treated with mineralocorticoids (fludrocortisone), the dose should be stable for at least 1 month prior to Screening without orthostatic hypotension, and with serum sodium and potassium in the normal range. 7. If on estrogen therapy (any route), the dose must be stable for at least 3 months prior to Screening.

What this trial measures

  • Proportion of participants with morning post-GC A4 ≤ ULN who are on physiologic GC replacement.Week 32